Rothschild Investment Corp IL reduced its position in Shire PLC (NASDAQ:SHPG) by 11.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,096 shares of the biopharmaceutical company’s stock after selling 1,177 shares during the period. Rothschild Investment Corp IL’s holdings in Shire PLC were worth $1,393,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Fisher Asset Management LLC grew its stake in shares of Shire PLC by 2.9% during the third quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock valued at $8,793,000 after buying an additional 1,619 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Shire PLC by 63.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock valued at $2,941,000 after purchasing an additional 6,917 shares during the period. Baldwin Investment Management LLC boosted its holdings in shares of Shire PLC by 1.4% in the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after purchasing an additional 23 shares during the period. Oak Ridge Investments LLC boosted its holdings in shares of Shire PLC by 3.2% in the second quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock valued at $13,389,000 after purchasing an additional 2,528 shares during the period. Finally, Federated Investors Inc. PA boosted its holdings in shares of Shire PLC by 38.8% in the second quarter. Federated Investors Inc. PA now owns 9,153 shares of the biopharmaceutical company’s stock valued at $1,513,000 after purchasing an additional 2,560 shares during the period. 18.27% of the stock is currently owned by institutional investors.
Shire PLC (NASDAQ:SHPG) traded down $2.04 during trading on Tuesday, reaching $138.32. 632,800 shares of the company traded hands, compared to its average volume of 1,135,001. Shire PLC has a 12-month low of $137.17 and a 12-month high of $192.15. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. The firm has a market cap of $42,167.93, a P/E ratio of 9.65, a PEG ratio of 0.78 and a beta of 1.60.
Shire PLC (NASDAQ:SHPG) last posted its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The firm had revenue of $3.70 billion during the quarter. During the same quarter last year, the business posted $3.17 EPS. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. research analysts predict that Shire PLC will post 15 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://weekherald.com/2017/11/15/rothschild-investment-corp-il-has-1-39-million-stake-in-shire-plc-shpg.html.
A number of analysts have weighed in on the company. BidaskClub downgraded Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Barclays PLC downgraded Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Evercore ISI began coverage on Shire PLC in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 target price on the stock. Royal Bank Of Canada reissued a “buy” rating and issued a $213.00 target price on shares of Shire PLC in a research report on Monday, October 2nd. Finally, Piper Jaffray Companies set a $159.00 price target on Shire PLC and gave the stock a “hold” rating in a research report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $211.00.
Shire PLC Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.